GAP161 targets and downregulates G3BP to suppress cell growth and potentiate cisplaitin-mediated cytotoxicity to colon carcinoma HCT116 cells

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1848-1856

  Zhang, Hao ^a   Zhang, Shenghua ^a   He, Hongwei ^a   Zhao, Wuli ^a   Chen, Jianhua ^b   Shao, Rong Guang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Wuhan KatyGen Pharmaceuticals   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GAP 161; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PEPTIDE GAP 161; PROTEIN SH3; RAS GTPASE ACTIVATING PROTEIN SH3 DOMAIN BINDING PROTEIN 1; RAS GTPASE ACTIVATING PROTEIN SH3 DOMAIN BINDING PROTEIN 2; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84867229869     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02361.x     Document Type: Article

References (34)

1. Barnes CJ, Li F, Mandal M, Yang Z, Sahin AA, Kumar R. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res 2002; 62: 1251-5.
2. French J, Stirling R, Walsh M, Kennedy HD. The expression of Ras-GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochem J 2002; 34: 223-31.
3. Guitard E, Parker F, Millon R, Abecassis J, Tocque B. G3BP is overexpressed in human tumors and promotes S phase entry. Cancer Lett 2001; 162: 213-21.
4. Taniuchi K, Nishimori I, Hollingsworth MA. Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP. Cancer Res 2011; 71: 895-905.
5. Taniuchi K, Nishimori I, Hollingsworth MA. The N-terminal domain of G3BP enhances cell motility and invasion by posttranscriptional regulation of BART. Mol Cancer Res 2011; 9: 856-66.
6. Gallouzi IE, Parker F, Chebli K et al. A novel phosphorylation-dependent RNase activity of GAP-SH3 binding protein: a potential link between signal transduction and RNA stability. Mol Cell Biol 1998; 18: 3956-65.
7. Prigent M, Barlat I, Langen H, Dargemont C. IkappaBalpha and IkappaBalpha/NF-kappa B complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2. J Biol Chem 2000; 275: 36441-9.
8. Soncini C, Berdo I, Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene 2001; 20: 3869-79.
9. Huang Y, Wernyj RP, Norton DD, Precht P, Seminario MC, Wange RL. Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN. Oncogene 2005; 24: 3819-29.
10. Kim MM, Wiederschain D, Kennedy D, Hansen E, Yuan ZM. Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP). Oncogene 2007; 26: 4209-15.
11. Tourriere H, Chebli K, Zekri L et al. The RasGAP-associated endoribonuclease G3BP assembles stress granules. J Cell Biol 2003; 160: 823-31.
12. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat Cell Biol 2008; 10: 1324-32.
13. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413.
14. Leblanc V, Tocque B, Delumeau I. Ras-GAP controls Rho-mediated cytoskeletal reorganization through its SH3 domain. Mol Cell Biol 1998; 18: 5567-78.
15. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007; 129: 865-77.
16. Michod D, Yang JY, Chen J, Bonny C, Widmann C. A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. Oncogene 2004; 23: 8971-8.
17. Yang JY, Widmann C. Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol Cell Biol 2001; 21: 5346-58.
18. Cui W, Wei Z, Chen Q et al. Structure-based design of peptides against G3BP with cytotoxicity on tumor cells. J Chem Inf Model 2010; 50: 380-7.
19. Chen W, Wang X, Bai L, Liang X, Zhuang J, Lin Y. Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J Cell Biochem 2008; 105: 554-61.
20. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5: 1007-14.
21. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51-9.
22. Yoon H, Min JK, Lee JW, Kim DG, Hong HJ. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun 2011; 405: 333-7.
23. Jiang X, Takahashi N, Ando K, Otsuka T, Tetsuka T, Okamoto T. NF-kappa B p65 transactivation domain is involved in the NF-kappa B-inducing kinase pathway. Biochem Biophys Res Commun 2003; 301: 583-90.
24. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005; 30: 43-52.
25. Sun HX, He HW, Zhang SH et al. Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition. Cancer Gene Ther 2009; 16: 693-702.
26. Ren K, Jin H, Bian C et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem 2008; 283: 35598-605.
27. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005; 446: 475-82.
28. He HN, Wang X, Zheng XL et al. Concurrent blockade of the NF-kappaB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity. Cancer Lett 2010; 295: 38-43.
29. Parker F, Maurier F, Delumeau I et al. A Ras-GTPase-activating protein SH3-domain-binding protein. Mol Cell Biol 1996; 16: 2561-9.
30. Kennedy D, French J, Guitard E, Ru K, Tocque B, Mattick J. Characterization of G3BPs: tissue specific expression, chromosomal localisation and rasGAP(120) binding studies. J Cell Biochem 2001; 84: 173-87.
31. Parker F, Kenigsberg M, Duchesne M, Barlat I. Monoclonal antibodies directed against the G3BP protein, and uses. US patent 7, 001, 980. 2006; 21 Feb.
32. Zhang H, Zhang S, He H et al. RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-kappaB in colon carcinoma HCT116 cells. Cancer Lett 2011; 308: 62-70.
33. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-5.
34. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998; 3: d887-912.